← Back

Fortive: Fortive Corporation's Q2 2025 Earnings Analysis

Fortive Corporation's Q2 2025 earnings call highlighted a successful spin-off of Precision Technologies, now Ralliant, and its emergence as a simpler, more focused company. The company delivered adjusted EPS of $0.58, up 4% year-over-year, and 14% growth in trailing 12-month free cash flow. Revenue was $1 billion, down 0.4% year-over-year, due to customer demand pressures in June stemming from tariff uncertainty, constrained government spending, and evolving healthcare policy dynamics. This performance was largely in line with expectations, with EPS slightly below analysts' estimates of $0.60.

FTV

USD 55.24

1.07%

A-Score: 4.4/10

Publication date: July 30, 2025

Author: Analystock.ai

πŸ“‹ Highlights
  • Spin-off Completion Fortive successfully spun off Precision Technologies, now Ralliant, and received a $1.15 billion dividend, using $725 million to pay down debt.
  • Q2 Financials Delivered adjusted EPS of $0.58 (4% YoY growth) and $1 billion in revenue, down 0.4% YoY, with 14% growth in trailing 12-month free cash flow.
  • Segment Performance AHS revenue was $320 million (1.3% YoY decline), while IOS saw flat revenue and core growth; adjusted gross and EBITDA margins remained steady.
  • Guidance Initiated FY adjusted EPS guidance of $2.50-$2.60, with Q3 revenue expected to match Q2 and Q4 EPS anticipated to rise significantly.
  • Market Challenges Faced headwinds in government spending and healthcare capital equipment, but expects easing in H2 with organic sales growth consistent with Q2 levels.

Segment Performance

The Intelligent Operating Solutions (IOS) segment saw flat revenue and core revenue growth year-over-year, while the Advanced Healthcare Solutions (AHS) segment delivered total revenue of $320 million, down 1.3% year-over-year. Adjusted gross margins were flat year-over-year, and adjusted EBITDA margins held steady. According to management, "Q2 played out as expected, except for three discrete items: the slowdown in government spending at Gordian, a selling days headwind in healthcare in Q1 that morphed into a more problematic slowdown in late Q2, and a slight shift in mix from short cycle to longer cycle in late June at Fluke."

Guidance and Outlook

Fortive is initiating its full-year adjusted EPS guidance at $2.50 to $2.60 per share, assuming a continuation of current market dynamics and the expected net impact of tariffs. The company expects Q3 reported revenue to be broadly similar to Q2 and second-half core revenue growth in the range of the core growth seen in the first half. Fortive expects Q4 adjusted EPS to be meaningfully higher than Q3, which is expected to be slightly lower than Q2. The company's management remains focused on driving accelerated growth and shareholder value creation, with a medium-term financial framework intact.

Valuation and Financial Metrics

At current prices, Fortive trades at a P/E Ratio of 20.56, a P/B Ratio of 1.52, and an EV/EBITDA of 14.37. The stock offers a Dividend Yield of 0.65% and a Free Cash Flow Yield of 8.8%. With a ROIC of 5.51% and ROE of 7.44, the company's financial performance appears solid. Net debt to EBITDA stands at 2.29, indicating a manageable debt burden. As analyst Sarah Jones from Morgan Stanley noted, "Fortive's spin-off and management change were not significant distractions for most operating companies, with the corporate team handling most of the spin activity."

Fortive's A-Score